Polaryx Therapeutics, Inc. PLYX
—
2.09
(0.05)
(2.34%)
as of 25 Sep
- Market cap
- $106.7M
- P/E
- 0.0×
Follow PLYX
Insider Buys
alert about insiders buying in the last 12 month
| Dec '24 | Dec '25 | |
|---|---|---|
Current Ratio |
17.30 | 8.55 |
Net Debt/EBITDA |
1.06 | 0.66 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
— | 0.00 |
Operating CF/Net income |
0.08 | 0.44 |
Interest Coverage |
0.00 | 0.00 |
| 0.00% | (193.70%) | |
| 0.00% | (176.68%) | |
ROIC |
(2,989.01%) | 0.00% |
Return on Tangible Assets |
(644.23%) | (196.82%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(0.08) | (0.09) |
Cash per Share |
0.14 | 0.11 |
Shareholders Equity per Share |
0.14 | 0.10 |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
0.14 | 0.10 |
Free Cash Flow |
(2.57) | (3.94) |
Working Capital |
4.71 | 4.57 |
Net Current Asset Value |
4.71 | 4.57 |
| Other line items | ||
Quick Ratio |
15.99 | 8.50 |
Cash ROIC |
(27.57%) | (40.63%) |
Accounts Payable Turnover |
— | 0.00 |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(0.08) | (0.09) |
Capex per Share |
0.00 | 0.00 |
Average Payables |
— | 0.27 |
Average Assets |
— | 5.09 |
Average Common Equity |
— | 4.64 |
Net Profit Margin |
0.00% | 0.00% |
Columns are period end dates